Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

The attorneys general sent a letter saying the FDA needs to take action because high demand for the weight loss drugs paired with shortages has created a market for counterfeits.

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...

Novo Nordisk Foundation, ultimate parent of weight loss drugs Ozempic and Wegovy, awards a grant to University of Copenhagen ...

Novo Nordisk revealed a stunning increase in pollution amid plans to boost production of its popular weight loss drug Wegovy.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

Novo Nordisk shares are experiencing a significant decline amidst intensified investor concerns over its competitiveness in ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...